AC Immune (ACIU) Competitors $2.43 +0.05 (+2.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 09/12/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. IMNM, AMLX, IOVA, PHAT, URGN, TRVI, DNTH, AVBP, AVXL, and ABUSShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Immunome (IMNM), Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Trevi Therapeutics (TRVI), Dianthus Therapeutics (DNTH), ArriVent BioPharma (AVBP), Anavex Life Sciences (AVXL), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors Immunome Amylyx Pharmaceuticals Iovance Biotherapeutics Phathom Pharmaceuticals Urogen Pharma Trevi Therapeutics Dianthus Therapeutics ArriVent BioPharma Anavex Life Sciences Arbutus Biopharma AC Immune (NASDAQ:ACIU) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has more risk and volatility, ACIU or IMNM? AC Immune has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Which has higher valuation and earnings, ACIU or IMNM? AC Immune has higher revenue and earnings than Immunome. AC Immune is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$31.02M7.87-$57.83M-$0.58-4.19Immunome$12.59M63.68-$292.96M-$3.08-2.99 Does the media prefer ACIU or IMNM? In the previous week, Immunome had 1 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Immunome and 7 mentions for AC Immune. Immunome's average media sentiment score of 1.46 beat AC Immune's score of 1.43 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ACIU or IMNM more profitable? AC Immune has a net margin of -174.94% compared to Immunome's net margin of -1,687.08%. AC Immune's return on equity of -49.35% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets AC Immune-174.94% -49.35% -23.16% Immunome -1,687.08%-76.10%-65.14% Do insiders and institutionals hold more shares of ACIU or IMNM? 51.4% of AC Immune shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 7.7% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ACIU or IMNM? AC Immune presently has a consensus price target of $10.00, suggesting a potential upside of 311.52%. Immunome has a consensus price target of $22.89, suggesting a potential upside of 148.52%. Given AC Immune's higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Immunome 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAC Immune and Immunome tied by winning 8 of the 16 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$238.98M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-4.1921.4375.4125.98Price / Sales7.87433.72515.95180.52Price / CashN/A46.6837.5660.44Price / Book1.889.6112.156.29Net Income-$57.83M-$53.29M$3.29B$271.07M7 Day Performance6.58%0.13%0.74%3.87%1 Month Performance14.08%5.55%5.00%5.49%1 Year Performance-23.58%10.44%62.55%25.86% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.6297 of 5 stars$2.43+2.1%$10.00+311.5%-23.6%$238.98M$31.02M-4.19140Positive NewsAnalyst UpgradeIMNMImmunome2.3386 of 5 stars$9.40-10.6%$22.89+143.5%-42.3%$915.71M$9.04M-3.0540Positive NewsAMLXAmylyx Pharmaceuticals1.7927 of 5 stars$10.44+2.4%$12.25+17.3%+344.7%$909.51M$87.37M-4.18200Positive NewsIOVAIovance Biotherapeutics4.4317 of 5 stars$2.38-4.4%$11.90+400.0%-78.0%$901.02M$164.07M-1.93500Positive NewsPHATPhathom Pharmaceuticals2.3731 of 5 stars$12.43+0.7%$17.50+40.8%-35.3%$875.45M$55.25M-2.63110Positive NewsURGNUrogen Pharma4.0677 of 5 stars$21.42+13.5%$32.00+49.4%+43.2%$873.47M$90.40M-6.45200News CoverageAnalyst UpgradeHigh Trading VolumeTRVITrevi Therapeutics2.8309 of 5 stars$7.60+8.4%$21.75+186.2%+144.8%$853.66MN/A-18.0920News CoveragePositive NewsHigh Trading VolumeDNTHDianthus Therapeutics2.8729 of 5 stars$31.80+20.0%$54.00+69.8%+28.3%$852.99M$6.24M-9.7880Trending NewsAnalyst ForecastInsider TradeHigh Trading VolumeAVBPArriVent BioPharma1.9586 of 5 stars$20.21+0.1%$39.14+93.7%-17.0%$819.09MN/A-5.0340Positive NewsAVXLAnavex Life Sciences3.6635 of 5 stars$9.35-0.5%$44.00+370.6%+76.5%$807.40MN/A-16.4040News CoveragePositive NewsAnalyst ForecastABUSArbutus Biopharma2.0027 of 5 stars$4.09-2.6%$5.00+22.2%-0.2%$805.13M$6.17M-14.1090News CoveragePositive News Related Companies and Tools Related Companies Immunome Competitors Amylyx Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Phathom Pharmaceuticals Competitors Urogen Pharma Competitors Trevi Therapeutics Competitors Dianthus Therapeutics Competitors ArriVent BioPharma Competitors Anavex Life Sciences Competitors Arbutus Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACIU Stock Alerts